OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.

Kejia HuPing HeQian PengXiaorong ZhongLing DengYuxin XieJiayuan LiHongping XuDonghao LuHong Zheng

Published in: Breast cancer (Tokyo, Japan) (2018)

Our findings suggest that OFS plus AI treatment may extend both iDFS and OS among premenopausal patients with hormone receptor-positive breast cancer in the real world.

Keyphrases

positive breast cancer
artificial intelligence
postmenopausal women
breast cancer risk
emergency department
combination therapy